The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients.
作者： Brent Emigh , Leslie Kobayashi , Miroslav Kopp , Mitch Daley , Lindsey Teal
DOI: 10.1016/J.AMJSURG.2020.12.034
关键词:
摘要: Abstract Background Drug-specific agents for the reversal of direct oral anticoagulants (DOACs) were recently approved. We hypothesized that approval these would lead improved outcomes trauma patients taking DOACs. Methods A multicenter, prospective (2015–2018), observational study all adult DOACs who admitted to one fifteen participating centers was performed. The primary outcome mortality. Results For 606 on DOACs, those reversed older (78 vs. 74, p = 0.007), more severely injured (ISS: 16 5, p Conclusions DOAC not independently associated with At present, overall usage drug-specific is too sparing meaningfully assess in trauma.
sci-hub.st 参考文章(31)
Mark Crowther, Gallia G. Levy, Genmin Lu, Janet Leeds, Joyce Lin, Pratikhya Pratikhya, Pamela B. Conley, Stuart Connolly, John T. Curnutte, A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors Blood. ,vol. 124, pp. 4269- 4269 ,(2014) , 10.1182/BLOOD.V124.21.4269.4269
Charles V. Pollack, Paul A. Reilly, John Eikelboom, Stephan Glund, Peter Verhamme, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Chak-Wah Kam, Jeffrey I. Weitz, Idarucizumab for Dabigatran Reversal The New England Journal of Medicine. ,vol. 373, pp. 511- 520 ,(2015) , 10.1056/NEJMOA1502000
Raphael Marlu, Enkelejda Hodaj, Adeline Paris, Pierre Albaladejo, Jean Crackowski, Gilles Pernod, Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thrombosis and Haemostasis. ,vol. 108, pp. 217- 224 ,(2012) , 10.1160/TH12-03-0179
M Levi, KT Moore, CF Castillejos, D Kubitza, SD Berkowitz, SZ Goldhaber, M Raghoebar, MR Patel, JI Weitz, JH Levy, None, Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers Journal of Thrombosis and Haemostasis. ,vol. 12, pp. 1428- 1436 ,(2014) , 10.1111/JTH.12599
Thomas Thiele, Kathleen Selleng, Andreas Greinacher, Reversal of anticoagulants: an overview of current developments Thrombosis and Haemostasis. ,vol. 113, pp. 931- 942 ,(2015) , 10.1160/TH14-11-0982
Marcello Di Nisio, Saskia Middeldorp, Harry R. Büller, Direct thrombin inhibitors. The New England Journal of Medicine. ,vol. 353, pp. 1028- 1040 ,(2005) , 10.1056/NEJMRA044440
Victor A. Ferraris, Andrew C. Bernard, Brannon Hyde, Paul A. Kearney, The impact of antiplatelet drugs on trauma outcomes Journal of Trauma and Acute Care Surgery. ,vol. 73, pp. 492- 497 ,(2012) , 10.1097/TA.0B013E31825B85F1
Lesly A. Dossett, Prevalence and Implications of Preinjury Warfarin Use Archives of Surgery. ,vol. 146, pp. 565- 570 ,(2011) , 10.1001/ARCHSURG.2010.313
Jack E. Ansell, Sasha H. Bakhru, Bryan E. Laulicht, Solomon S. Steiner, Michael Grosso, Karen Brown, Victor Dishy, Robert J. Noveck, James C. Costin, Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban New England Journal of Medicine. ,vol. 371, pp. 2141- 2142 ,(2014) , 10.1056/NEJMC1411800
Charles V Pollack Jr, Paul A Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom, Stephan Glund, Menno V Huisman, Elaine Hylek, Chak-Wah Kam, Pieter W Kamphuisen, Joerg Kreuzer, Jerrold H Levy, Frank Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, Jeffrey I Weitz, Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran Thrombosis and Haemostasis. ,vol. 114, pp. 198- 205 ,(2015) , 10.1160/TH15-03-0192